FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period

FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register